EGFR and colorectal cancer: Although this technology was developed in 1994, the first human mAb based on transgenic mice technology (i.e., panitumumab) was only approved by the FDA and EMA in 2006 and 2007, respectively, to treat patients with colorectal cancer harboring epidermal growth factor receptor (EGFR) mutations [20].